-
Blog BLOG
-
Product Center BRAND DYNAMICS
-
Investor INVESTOR RELATIONS
-
Contact Us CONTACT
-
Supervise SUPERVISION
Healthy Yuan (600380.SH): Key data obtained in Phase III clinical trial of sequential booster immunization with recombinant COVID-19 fusion protein vaccine of Lizhu.
Published Time:
2022-02-17
GELONGHUI February 16 | Jiankangyuan (600380.SH) announced that its subsidiary, Lizhu Pharmaceutical Group Co., Ltd.'s subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd. (referred to as "Lizhu Monoclonal Antibody"), has completed the interim primary data analysis of the Phase III clinical trial of its "recombinant novel coronavirus fusion protein vaccine" and obtained key data.
This sequential booster regimen is designed as a sequential booster based on two doses of inactivated vaccine, using a relatively strong and superior protection standard, which is different from the traditional blank placebo regimen. V-01 conducted Phase III clinical trials of sequential boosting in Pakistan and Malaysia, planning to inject V-01 booster or blank placebo in a 1:1 ratio among a total of 10,722 healthy adults aged 18 and above who completed 2 doses of inactivated vaccine 3-6 months ago.
As of the date of this key data analysis, 10,241 people were actually enrolled, and a total of 110 cases of primary endpoint events were monitored after vaccination (the protocol requires analysis when at least 103 primary endpoint cases are available). According to the results of the current stage analysis: Compared with two doses of inactivated vaccine, the annual incidence rate of the V-01 sequential booster group and the two-dose inactivated vaccine group were 6.73% and 12.80%, respectively, with a significant difference (P=0.0012); the absolute protective efficacy of V-01 sequential booster was 61.35%, with significantly superior efficacy. The absolute protective efficacy of V-01 sequential booster has met the WHO standard. The genotyping sequencing of 60 of all the effectively tested samples in this trial was Omicron (the rest are still undergoing second-generation sequencing), indicating that V-01 sequential booster can produce good protection against COVID-19 caused by Omicron infection. At the same time, no safety concerns of note were found.
According to the LSHTM tracker, as of February 7, 2022, there were 121 COVID-19 vaccine products in clinical trials worldwide, of which 27 have been approved for marketing or emergency use. In China, 4 have received conditional approval (no recombinant protein technology route products), 7 have received emergency use approval (including 1 recombinant protein technology route product), and a total of 21 are in clinical trials (8 recombinant protein technology route products).
To date, Lizhu Monoclonal Antibody has accumulated approximately RMB 509 million in direct R&D investment in the V-01 project (including I/II phase clinical trials, sequential boosting and basic immunization III phase clinical trials).
From: GELONGHUI
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Sorry,当前栏目暂无内容!
您可以查看其他栏目或返回 首页
Sorry,The current column has no content!
You can view other columns or return Home